Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

41.73 0.12 −0.29%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by segment Fiscal 2025

  • United States
  • Europe
  • International Markets
  • Other Activities

Every year since 2015 →

Insider Decisions last twelve months

Sold, $m 105.42
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 4 — 2 17 1 5 4 — 6 2 — —
Insider Ownership 4.80%

Capital & Financial Ratios $m

Size
Market Cap 48,690.00
Revenue ttm 17,230.00
Net income ttm 508.00
Free cash flow ttm 1,328.00
Net debt Q 12,633.00
Valuation
P/E 92.59 (above 35: high)
Forward P/E 30.70
Price / sales 2.82
Forward P/S Powerpack
Price / FCF 36.64
Price / book 6.09 (above 6: high)
Financial health
Current ratio Q 0.95 (below 1: weak)
Debt / equity Q 2.09 (above 2: weak)
Interest coverage Q —
Growth
Revenue growth Q −1.90% (below 0%: shrinking)
Operating income growth Q −19.05% (below 0%: shrinking)
EPS, this year −29.94% (below 0%: weak)
EPS, next year A +51.71% (at or above 15%: strong)
Revenue, next year A −3.80% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +6.11%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 2.2×; over the ten years it ranged from 1.8× in 2023 to 3.9× in 2016.
P/E against its own 10 years 83.72%
10-year low 10-year high
P/S against its own 10 years 99.78%
10-year low 10-year high
P/B against its own 10 years 99.89%
10-year low 10-year high
EV/Sales against its own 10 years 98.61%
10-year low 10-year high
EV/FCF against its own 10 years 69.49%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2016–25
−100.0%/yr
  1. 1.36 ’16
  2. 0.85 ’17 −38
  3. 0.00 ’21 −100
  4. 0.00 ’22
  5. 0.00 ’23
  6. 0.00 ’24
  7. 0.00 ’25
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3,226 3,300 3,556 4,085
Receivables 3,408 3,059 3,709 3,837
Inventory 4,021 3,007 3,179 3,173
Other 504 409 539 658
12,485 12,552 13,946 14,602
2023 2024 2025 Q'26
Payables 2,602 2,203 2,531 2,551
ST’ Debt 1,672 1,781 1,820 4,038
Other 4,579 4,698 5,325 4,991
12,247 12,796 13,456 15,425

Compound Annual Growth %

10y 5y 3y
Sales (1.29%) 0.71% 4.96%
Cash Flow (11.42%) 6.28% 1.22%
Earnings (1.09%) 0.00% 0.00%
Book Value (12.45%) (6.48%) (2.73%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.72 Actual 0.86

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.65 0.96 Beat by 0.31
Q1 FY26 0.50 0.53 Beat by 0.03
Q2 FY26 0.08 0.02 Miss by 0.06
Q3 FY26 0.72 0.86 Beat by 0.14
Q4 FY26 0.80 — Reports 27 January 2027

EPS $

Mar Jun Sep Dec Year
’26 0.31 (0.49) 0.20 — —
’25 0.18 0.24 0.37 0.41 1.21
’24 (0.12) (0.75) (0.39) (0.19) (1.45)
’23 (0.18) (0.77) 0.07 0.41 (0.50)
’22 (0.86) (0.21) 0.05 (1.10) (2.12)
’21 0.07 0.19 0.26 (0.14) 0.38
’20 0.06 0.13 (3.97) 0.14 (3.64)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3,982 4,142 4,395 — —
’25 3,891 4,176 4,480 4,711 17,258
’24 3,819 4,164 4,332 4,229 16,544
’23 3,661 3,878 3,850 4,457 15,846
’22 3,661 3,786 3,595 3,883 14,925
’21 3,982 3,910 3,887 4,099 15,878
’20 4,357 3,870 3,978 4,454 16,659
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (40) 411 241 — —
’25 (105) 227 369 1,158 1,649
’24 (124) 103 693 575 1,247
’23 (145) 324 5 1,184 1,368
’22 (49) 123 543 973 1,590
’21 (405) 218 529 456 798
’20 305 273 307 331 1,216
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (166) 310 168 — —
’25 (215) 140 241 1,016 1,182
’24 (248) 7 583 450 792
’23 (282) 261 (134) 1,065 910
’22 (181) 14 423 854 1,110
’21 (417) 221 398 345 547
’20 183 181 173 168 705
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 18.6% a year for ten years. It grew −19.1% a year over the last ten.

Implied
18.6%
10 years, reported
−19.1%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 21,903 22,385 18,271 16,887 16,659 15,878 14,925 15,846 16,544 17,258 17,230 (2.6%) 16,602 17,318 18,105 +1.6%
Gross margin, % 54.14 47.42 45.41 44.63 46.38 47.83 46.72 48.25 48.74 51.79 53.51 (2.3) pt
EBT 824 (18,379) (2,596) (1,265) (4,406) 658 (3,163) (624) (1,284) 1,223 362 +4.5%
EBT margin, % 3.76 (82.10) (14.21) (7.49) (26.45) 4.14 (21.19) (3.94) (7.76) 7.09 2.10 +3.3 pt
Net income 311 (16,449) (2,472) (1,000) (4,099) 456 (2,499) (615) (1,959) 1,418 508 +18.4%
Per share, $
Per share, $ Revenue 22.94 22.03 17.90 15.48 15.21 14.41 13.45 14.16 14.63 15.07 14.78 (4.6%)
Earnings 0.07 (16.26) (2.35) (0.91) (3.64) 0.38 (2.12) (0.50) (1.45) 1.23 0.45 +37.5%
Cash flow 5.47 2.19 2.40 0.69 1.11 0.72 1.43 1.22 1.10 1.44 1.52 (13.8%)
Capex 1.15 2.56 0.23 (0.17) (0.47) (0.23) (0.43) (0.41) (0.40) (0.41) (0.38) n/m
Free cash flow 6.62 4.75 2.63 0.52 0.64 0.50 1.00 0.81 0.70 1.03 1.14 (18.7%)
Book value 36.64 18.45 15.47 13.81 10.10 10.20 7.75 7.26 4.76 6.91 6.85 (16.9%)
Shares, m 955 1,016 1,021 1,091 1,095 1,102 1,110 1,119 1,131 1,145 1,158 +2.0%
Valuation, ×
Valuation, × P/E 535.43 0.00 0.00 0.00 0.00 22.76 0.00 0.00 0.00 25.17 92.59 58.3
P/S 1.63 0.68 0.86 0.63 0.63 0.60 0.71 0.75 1.51 2.07 2.82 1.0
P/B 1.14 1.01 1.00 0.71 0.96 0.85 1.23 1.47 4.63 4.52 6.09 1.8
EV/Sales 3.22 2.09 2.35 2.11 2.06 1.92 1.94 1.80 2.38 2.84 3.56 2.3
EV/FCF 11.16 9.68 15.97 62.94 48.66 55.59 26.12 31.37 49.76 41.44 46.15 35.3
Cash, $m
Cash, $m Operating cash flow 5,225 2,225 2,446 748 1,216 798 1,590 1,368 1,247 1,649 1,770 (12.0%)
Capex 1,101 2,603 239 (182) (511) (251) (480) (458) (455) (467) (442) n/m
Free cash flow 6,326 4,828 2,685 566 705 547 1,110 910 792 1,182 1,328 (17.0%)
Balance, $m
Balance, $m Working capital (1,260) (2,539) (528) (210) (159) 1,546 582 238 (244) 490 (823) n/m
Net debt 34,812 31,512 27,134 24,932 23,742 20,878 18,411 16,607 14,483 13,250 12,633 (10.2%)
Shareholders’ equity 34,993 18,745 15,794 15,063 11,061 11,244 8,598 8,126 5,380 7,914 7,984 (15.2%)
Returns, %
Returns, % ROA 0.09 (20.19) (3.65) (1.69) (7.38) 0.85 (5.34) (1.28) (3.96) 3.52 1.27 +3.4 pt
ROIC 1.93 (21.74) 2.02 (0.69) (6.41) 3.34 (5.08) 1.09 3.07 6.37 4.09 +4.4 pt
ROE 0.23 (71.10) (15.52) (6.48) (30.55) 3.74 (24.65) (6.69) (24.27) 21.21 6.65 +21.0 pt
People
People Employees 56,960 51,792 42,535 40,039 40,216 37,537 36,826 37,851 36,830 33,950 — (5.6%)
Revenue/emp, $m 0.38 0.43 0.43 0.42 0.41 0.42 0.41 0.42 0.45 0.51 — +3.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Business profile

Updated

Teva Pharmaceutical Industries is a biopharmaceutical company that develops, manufactures and sells medicines worldwide. It was founded in 1944, is headquartered in Ramat HaHayal, Israel, and is led by President and Chief Executive Officer Richard Francis.

A substantial part of its business is generic medicines: versions of established drugs that have the same chemical and therapeutic properties as their brand-name equivalents. Teva also sells biosimilars, which are highly similar versions of biologic medicines made from living cells or organisms. Its portfolio includes over-the-counter products and medicines developed under its own brands.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
United States 9,186 53.23%
Europe 5,040 29.20%
International Markets 2,162 12.53%
Other Activities 870 5.04%
Gross margin 51.79%
Operating margin 12.50%
Pre-tax margin 7.09%

Revenue by segment since 2015

Teva Pharmaceutical Industries Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TAK Takeda Pharmaceutical Co. $67.7B 32.0× — +1.71% (above 0%: growing) −4.35% (below 0%: shrinking) +54.88% (above 0%: growing) 66.66% 16.51% Compare
TEVA Teva Pharmaceutical Industries Ltd. $48.7B 92.6× 30.7× −1.90% (below 0%: shrinking) −47.18% (below 0%: shrinking) −30.29% (below 0%: shrinking) 55.52% 16.25%
HLN Haleon PLC Sponsored ADR $40.2B 20.5× 16.5× −0.32% (below 0%: shrinking) +40.00% (above 0%: growing) −42.94% (below 0%: shrinking) 62.88% 25.36% Compare
ZTS Zoetis Inc. $33.9B 13.4× 14.2× −0.24% (below 0%: shrinking) +2.48% (above 0%: growing) +17.43% (above 0%: growing) 72.73% 37.56% Compare
UTHR United Therapeutics Corporation $24.3B 19.7× 22.5× +4.13% (above 0%: growing) −21.65% (below 0%: shrinking) −63.65% (below 0%: shrinking) 88.10% 36.97% Compare
VTRS Viatris Inc. $21.8B — (loss-making) 82.6× −0.28% (below 0%: shrinking) n/m +38.78% (above 0%: growing) 38.35% 6.97% Compare
NBIX Neurocrine Biosciences, Inc. $16.2B 23.0× 20.6× +41.24% (above 0%: growing) −3.67% (below 0%: shrinking) +79.00% (above 0%: growing) 97.63% 29.51% Compare
RDY Dr. Reddy's Laboratories Ltd $12.1B 44.4× 30.7× −10.09% (below 0%: shrinking) −36.84% (below 0%: shrinking) −70.49% (below 0%: shrinking) 52.13% 14.63% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 161× +10.23% (above 0%: growing) +450.00% (above 0%: growing) +35.56% (above 0%: growing) 58.33% 7.97% Compare
Median of peers $23.0B 21.7× 22.5× +0.74% −3.67% +26.50% 64.77% 20.93%

All 84 Drug Manufacturers Specialty & Generic stocks →

From the latest earnings call

Updated

  • CEO Richard Francis said growth in AUSTEDO, AJOVY and UZEDY helped offset lower generic sales, while Teva expanded its biosimilar portfolio.
  • CFO Eli Kalif said Teva expects fourth-quarter AUSTEDO revenue to decline and little WELTRUZA revenue as it establishes payer coverage.

Teva Pharmaceutical Industries Ltd. (TEVA) Latest News

5 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · Insider Monkey

4 Nov

Impact 3 · · Zacks
Impact 3 · · MarketBeat transcript

3 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire earnings
Impact 3 · · Simply Wall St.
Impact 3 · · MT Newswires
Impact 3 · · GlobeNewswire

2 Nov

Impact 3 · · GlobeNewswire

30 Oct

Impact 3 · · The Motley Fool

29 Oct

Impact 3 · · TIKR
Impact 3 · · Zacks

27 Oct

Impact 4 · · GlobeNewswire

23 Oct

Impact 4 · · Simply Wall St.

21 Oct

Impact 4 · · clinicaltrialsarena.com

20 Oct

Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire

13 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Zacks

12 Oct

Impact 4 · · Barchart
Impact 4 · · Zacks
Impact 4 · · Insider Monkey
Impact 4 · · pharmaceutical-technology.com
Impact 3 · · GlobeNewswire

9 Oct

Impact 4 · · Stocktwits
Impact 4 · · MarketBeat
Impact 4 · · Investing.com
Impact 4 · · Business Wire
Impact 3 · · Zacks

TEVA metrics, ten years each

stockrow.com/TEVA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com